Browse Studies — Arctuva

Phase 2

A Multi-center, Phase 2 Clinical Study of an Autologous Anti-CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy, Prizloncabtagene Autoleucel (Prizlon-cel), for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen recept…

Large B Cell LymphomaLBCLDiffuse Large B Cell Lymphoma (DLBCL)+8 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.